To The Moon

$CapLand IntCom T(C38U.SI)$ has risen 4.11% since the beginning of this year. Is it a good time to buy, sell or hold CICT?Let's do a deep dive into CICT. CICT is the largest REIT in Singapore with a market capitalisation of 13.5 billion dollars. Its portfolio comprises of 20 properties in Singapore, 2 in Frankfurt Germany and 2 in Sydney Australia with a total property value of SGD22. 9 billion as at 31 December 2021.CICT is a subsidiary of $CapitaLandInves(9CI.SI)$ , backed by Temasek Holdings.According to financial analysts from DBS, Maybank, OCBC, UOB Kay Hian and CGS-CIMB, CICT is a BUY with target price ranging from 2.5 to 2.57.The latest news on CICT is that it i

3 stocks to buy in April 2022Equity prices have fallen over the recent months on fears of high inflation and a hawkish Fed. The S&P 500 index has fallen 5.83% while the high-flying Nasdaq has fallen 12.24% year-to-date. For investors with a long time horizon, the recent market selloff may present an opportunity to purchase some high-quality stocks at reasonable prices. In this article, I highlight 3 stocks worth looking into for investors looking to buy high-quality companies at a reasonable price (GARP).Stock screenerTo screen for high-quality stocks trading at reasonable prices I used the following criteria: Large Market Cap (>$10B) Located in the US Low Debt-to-Equity ratio (<0.2) Inexpensive P/FCF (<30) High operating margin (>25%) Positive sales growth in the past

Shares of COVID-19 vaccine maker and biopharma behemoth Pfizer (PFE) have slipped into a correction on the back of the broader market sell-off. Now down around 16% from its peak just north of $60 per share, Pfizer is at a crossroads. With COVID-19 cases picking up rapidly in China, there are reasons to be concerned that another wave could hit North America this Spring. Just as the restrictions were easing and masks were coming off, another round of restrictions and booster shots (fourth doses for some) could be in the cards. While the pandemic is a concern that’s fallen into the background of late, it is still worth noting that we’re not yet in an endemic quite yet. As cases of the next variant (BA.2) look to pick up, there’s a real risk that COVID-19 may, once ahead, hog the headlines and

Pfizer stock may be the latest contender for your watchlist as shares set up to score a breakout from a new buy point. The pharmaceutical company is also awaiting authorization of its second Covid booster shot from the Food and Drug Administration, a decision that could impact Pfizer shares. Pfizer $Pfizer(PFE)$ , the largest pharmaceutical company in the world by annual revenue, is Monday's IBD 50 Stocks To Watch pick. New York-based Pfizer is forming the handle of a cup-with-handle base over the past week. The handle creates a 55.40 buy point, according to MarketSmith pattern recognition. Pfizer stock has pulled back in light volume to form the handle, which is exactly the kind of action investors want to see. The stock retook its 50

Is now the best time to buy these three Wood picks?

Second quarter GDP fell 2% q/q, compared with -1.8% estimate. Year-on-year growth surged 14.3%, rebo

TOKYO (Reuters) - The U.S. dollar touched a three-month high versus the euro and a one-week high ver